①求購下列各省藥材標(biāo)準(zhǔn)PDF版（價(jià)格為50元/本）： 河北省中藥材標(biāo)準(zhǔn) 江西省中藥材標(biāo)準(zhǔn)1996年版、2014年版 山東省中藥材標(biāo)準(zhǔn) 1995年版 河南省中藥材標(biāo)準(zhǔn)1993年版 湖南省中藥材標(biāo)準(zhǔn)1993版 湖北省中藥材質(zhì)量標(biāo)準(zhǔn)2019 四川中藥材標(biāo)準(zhǔn) 1987版增補(bǔ)本 貴州省中藥材質(zhì)量標(biāo)準(zhǔn) 1988 云南省中藥材質(zhì)量標(biāo)準(zhǔn)2010年版 云南省中藥材標(biāo)準(zhǔn)2005年版 5冊(cè)傣族藥2、 第6冊(cè)彝族藥3 陜西省藥品標(biāo)準(zhǔn)3 1976年版 青海藥品標(biāo)準(zhǔn)1976年 廣西壯族自治區(qū)瑤藥材質(zhì)量標(biāo)準(zhǔn) 第1卷 2014年版 西藏自治區(qū)藏藥材標(biāo)準(zhǔn) 第一冊(cè) 維吾爾藥材標(biāo)準(zhǔn)上、下冊(cè)（新疆維吾爾自治區(qū)衛(wèi)生廳編新疆科技衛(wèi)生出版社1993） 新疆維吾爾自治區(qū)維吾爾藥材標(biāo)準(zhǔn)2010年版 ②PDF文件要求：真實(shí)、無水印、完整、清晰，來源可靠（非網(wǎng)上百度所得）。 ③若發(fā)現(xiàn)文件有誤或缺損，相應(yīng)扣除一定的賞金。   [更多]

1、American Conference of Governmental Industrial Hygienists TLVs and BEIs. Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices. Cincinnati, OH, 2008, 2、內(nèi)容：Totsuka K，F(xiàn)urukawa M，F(xiàn)uruya N，et al. PK/PD analysis of Tebipenem Pivoxil (ME1211),a Novel Oral Carbapenem Antibiotic,in otolaryngological infections,a phase II clinical trial （3）.45th Intersci Conf Antimicrob Agents Chemother（ICAAC）（Dec 16-19. Washington，D.C.），2005，Abst L-579標(biāo)題 PK/PD analysis of Tebipenem Pivoxil (ME1211),a Novel Oral Carbapenem Antibiotic,in otolaryngological infections,a phase II clinical trial； 3、PK–PD analysis of tebipenem pivoxil in clinical trials for pediatric patients. Jpn J Chemother. 2009;57(S-1):186–91. 4、Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. González MA1, Straughan AB. 5、Single dose study of the bioequivalence of two sustained-release theophylline formulations. Contreras J, Pérez N, González R, Ontivero E, López M. Arzneimittelforschung. 1998 Mar;48(3):259-62. 6、National Technical Information Service. (Springfield, VA 22161) Formerly U.S. Clearinghouse for Scientific & Technical Information., AD277-689 7、Graul, A.; Castaner, J.; Atorvastatin Calcium. Drugs Fut 1997, 22, 9, 956. 8、Formulation And Evaluation of Topical Aceclofenac Gel Using Different Gelling Agent（JAPAN PATEL1*, BRIJESH PATEL1, HARDEEPSINGH BANWAIT1, KAUSHAL PARMAR1,MANISH PATEL2 Department of Pharmaceutics, Sat Kaival College of Pharmacy, Sarsa, Anand, Gujarat, India Nootan Pharmacy College, Visnagar, Gujarat, India） 9、NCCN pediatric neuroblastoma practice guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996 Dec;10(12):1813-22 10、Preliminary studies on toxic effects of some vulcanizing accelerators 11、Dose Dumping Dose dumping is an increased concern with drugs manufactured as modified-release (MR) formulations, that is, where drug   [更多]

目前有4500+條ATC多編碼數(shù)據(jù)需要?jiǎng)澐种鞔侮P(guān)系（即一個(gè)藥對(duì)應(yīng)的主要或關(guān)鍵適應(yīng)癥排序，最主要最關(guān)鍵的適應(yīng)癥排在前面，其次依序排列），已將數(shù)據(jù)分為多個(gè)數(shù)據(jù)包，每個(gè)數(shù)據(jù)包里包含了200個(gè)左右的藥品通用名，500元一個(gè)數(shù)據(jù)包（必須在規(guī)定時(shí)間完成并保證高的準(zhǔn)確度）。 每人每次只可領(lǐng)取一個(gè)數(shù)據(jù)包，一個(gè)數(shù)據(jù)包的處理時(shí)間為3天。數(shù)據(jù)審核合格以后付款，完成優(yōu)秀者，可重復(fù)領(lǐng)取數(shù)據(jù)包。 人員要求： （1）藥學(xué)本科及以上學(xué)歷或有中級(jí)職稱； （2）英語水平較好； （3）精通ATC編碼或以前參與過藥智網(wǎng)西藥ATC分類，且完成工作較好者。 PS:此貼用于領(lǐng)取任務(wù)，發(fā)布獎(jiǎng)金時(shí)在另行發(fā)布帖子由任務(wù)接收者單獨(dú)領(lǐng)取，完成質(zhì)量較好者會(huì)有額外獎(jiǎng)勵(lì)   [更多]

1、Effect of probenecid or diet on tebipenem pivoxil tablets pharmacokinetics in healthy male volunteers； 2、Effect of diet on the pharmacokinetics of tebipenem pivoxil fine granules in healthy male volunteers； 3、Pharmacokinetics analysis of tebipenem pivoxil in a phase II clinical trial in otolaryngological infection 1、Pharmacokinetic properties of isosorbide-5-mononitrate under fasting and fed conditions in healthy male subjects. Jin C, Jeon JY, Im YJ, Jeong JA, Kim Y, Chae SW, Bentz J, Kumke T, Kim MG. 7.The control of myopia with atropine.   [更多]

1.Myopia Control with Bifocal Contact Lenses:?A Randomized Clinical Trial 2.The Role of Atropine Eye Drops in Myopia Control 4. Myopia Control: A Review 7. Efficacy of 1%?atropine?eye drops in retarding progressive axial myopia in Indian eyes 8.Atropine?0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia 9.Current approaches to myopia control 10.Atropine?for the Prevention of Progression in Myopia - Data, Side Effects, Practical Guidelines 13. Atropine?0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia. 18. The treatment of myopia with?atropine?and bifocals. A long-term prospective study 19. Inhibitory effects of apomorphine and?atropine?and their combination on myopia in chicks 20. The penetration and distribution of topical?atropine?in animal ocular tissues. 21. Treatment outcomes of?myopic?anisometropia with 1%?atropine: a pilot study 23. Does?atropine?use increase intraocular pressure in?myopic?children? 24. Atropine?use for the prevention of myopia progression 25. Allergic reactions to?atropine?eye drops for retardation of progressive myopia in children. 29. Maximum?atropine?dose without clinical signs or symptoms. 31. Atropine?and bifocals can slow the progression of myopia in children. 33. Prevention of myopia onset with 0.025%?atropine?in premyopic children 35. The long-term results of using low-concentration?atropine?eye drops for controlling myopia progression in schoolchildren. 37. Prevention of myopia progression with 0.05%?atropine?solution.   [更多]

根據(jù)已知企業(yè)名稱（寫法不規(guī)范） 去CFDA http://app1.sfda.gov.cn/datasearchcnda/face3/base.jsp?tableId=25&tableName=TABLE25&title=%B9%FA%B2%FA%D2%A9%C6%B7&bcId=152904713761213296322795806604 或 藥智數(shù)據(jù)https://db.yaozh.com/pijian 查找對(duì)應(yīng)的規(guī)范企業(yè)名稱 無法確認(rèn)的需備注好原因 規(guī)范數(shù)據(jù)按照0.05元/條（10000條500元） 備注數(shù)據(jù)按照0.01元/條（10000條100元） 準(zhǔn)確率要求98%。   [更多]

1、P. A. Prajapati and M. M. Patel, “Formulation and in vitro evaluation of atropine sulphate viscous ocular solutions for the mydriatic and cycloplegic effect,”?International Journal of Pharmaceutical and Applied Sciences, vol. 1, no. 2, pp. 70–78, 2010.?View at Google Scholar 2、D. S. Satya, K. P. Suria, and P. P. Muthu, “Advanced approaches and evaluation of ocular drug delivery system,”?American Journal of PharmTech Research, vol. 1, no. 4, pp. 72–92, 2011.?View at Google Scholar 3、B. K. Nanjwade, D. B. Sonaje, and F. V. Manvi, “In vitro—in vivo?release of ciprofloxacin from ophthalmic formulations,”?International Journal of Pharmacy and Biotechnology, vol. 1, no. 1, pp. 23–28, 2011.?View at Google Scholar 4、Physicochemical properties and stability of nicorandil By Nagai, Hiroshi; Koizumi, Ikue; Haneda, Masatoshi; Imai, Toshikatsu; Kikuchi, Mineo; Shiba, Motoharu From Iyakuhin Kenkyu (1983), 14(6), 968-79. Language: Japanese, Database: CAPLUS 5、Sobean oil partially hydrogenated 最新德國(guó)藥典   [更多]

1.Arzneimittel Forschung/Drug research 1986 36(2)，p291-303. 2.The use of antithrombotic drugs in artery disease 3. Jonassen IB, Havelund S, Ribel U, et al. Insulin Degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer ormation [J]. Diabetes, 2010, 59(Suppll): All(39-OR). 4.Korsatko S, Deller S, Zahiragic S, et al. Ultra-long-acting insulin degludec: two different formulations (U100 and U200) are bioequivalent and show similar pharmacodynamics [abstract no. 2349-PO]. Diabetes. 2011;60 Suppl:A624. 5.Technology Reports of the Osaka University, , vol. 7, p. 177,182。   [更多]

1、Drugs Fut 1989, 14(9): 875 ISSN 0377-8282 Copyright Clarivate Analytics CCC: 0377-8282 DOI: 10.1358/dof.1989.014.09.103408 2、Dionne, G. (BioChem Pharma Inc.); 1,3-Oxathiolane nucleoside analogues. EP 0526253; JP 1995500317; US 5538975; WO 9303027 . 3、Hoshi, A.; Casta?er, J.; Capecitabine. Drugs Fut 1996, 21, 4, 358 4、Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1997, vol. 36, # 9, p. 816 - 818 5、DETERMINATION OF CLENBUTEROL HYDROCHLORIDE BY SEQUENTIAL INJECTION ANALYSIS COUPLED WITH CHEMILUMINESCENCE DETECTION 6、[Bioanalytic examination and pharmacokinetics of captopril. Bioequivalence studies of different captopril-containing Tensiomin preparations]. 7、Agrati A. M., De Bartolo G., Palmieri G., Minerva Med., 83, 533-536(1992) 8、Dawes J., Hodson B. A., Pepper D. S., Thromb. Haemost, 62, 945-949(1989) 9、with mercury(II) diacetate,trifluoroacetic acid . Acta Chimica Hungarica 1986 vol.122 3-4 p261-272   [更多]

①從任務(wù)主手中獲取指定年報(bào)數(shù)量的年報(bào)文件（PDF） ②將年報(bào)中“利潤(rùn)或合并利潤(rùn)”、“研發(fā)或研發(fā)投入”、“行業(yè)產(chǎn)品地區(qū)收入”、“治療領(lǐng)域”、“產(chǎn)銷量”、“產(chǎn)品研發(fā)投入明細(xì)”等數(shù)據(jù)填入相應(yīng)表格中（任務(wù)主提供填寫模板） ③要求仔細(xì)認(rèn)真，有責(zé)任心。 ④價(jià)格2.5元/份年報(bào)預(yù)計(jì)252份，一人84份（210元），3人共計(jì)630元。 ⑤若審核發(fā)現(xiàn)有錯(cuò)填、漏填，以每漏填，錯(cuò)填一個(gè)數(shù)據(jù)1元計(jì)量扣除賞金 ⑥以前合作做過類似項(xiàng)目的優(yōu)先考慮，如有感興趣的威客可聯(lián)系參與。   [更多]